11/15/2019  5:36:16 PM Chg. +0.200 Volume Bid11/15/2019 Ask11/15/2019 Market Capitalization Dividend Y. P/E Ratio
10.700EUR +1.90% 10,114
Turnover: 107,992.200
-Bid Size: - -Ask Size: - 28.74 mill.EUR 0.00% -

Business description

CytoTools AG is a biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology.
 

Management board & Supervisory board

CEO
Dr. Mark-Andre Freyberg
Management board
Dr. Dirk Kaiser
Supervisory board
Dr. Manfred May, Dr. Bernhard Seehaus, Dr. Rüdiger Weseloh, Heiner Hoppmann, Matthias Hoffmann, Prof. Dr. Peter Friedl
 

Company data

Name: CytoTools AG
Address: Klappacher Straße 126,D-64285 Darmstadt
Phone: +49-6151-951-5812
Fax: +49-6151-951-5813
E-mail: kontakt@cytotools.de
Internet: www.cytotools.de/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 78.00%
IPO date: -

Investor relations

Name: Dr. Mark-Andre Freyberg
IR phone: -
IR Fax: -
IR e-mail: -

Main Shareholders

Freefloat
 
78.00%
Organbesitz
 
22.00%